- Home
- KMDA vs SIGA Comparison
KMDA vs SIGA Comparison
Compare KMDA & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMDA
- SIGA
- Stock Information
- Founded
- KMDA 1990
- SIGA 1995
- Country
- KMDA Israel
- SIGA United States
- Employees
- KMDA N/A
- SIGA N/A
- Industry
- KMDA Biotechnology: Pharmaceutical Preparations
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- KMDA Health Care
- SIGA Health Care
- Exchange
- KMDA Nasdaq
- SIGA Nasdaq
- Market Cap
- KMDA 399.7M
- SIGA 422.9M
- IPO Year
- KMDA N/A
- SIGA 1997
- Fundamental
- Price
- KMDA $7.74
- SIGA $6.68
- Analyst Decision
- KMDA Strong Buy
- SIGA
- Analyst Count
- KMDA 3
- SIGA 0
- Target Price
- KMDA $14.67
- SIGA N/A
- AVG Volume (30 Days)
- KMDA 83.7K
- SIGA 412.1K
- Earning Date
- KMDA 08-13-2025
- SIGA 07-31-2025
- Dividend Yield
- KMDA 2.56%
- SIGA 9.02%
- EPS Growth
- KMDA 31.21
- SIGA N/A
- EPS
- KMDA 0.28
- SIGA 0.67
- Revenue
- KMDA $167,235,000.00
- SIGA $120,330,310.00
- Revenue This Year
- KMDA $14.51
- SIGA N/A
- Revenue Next Year
- KMDA $9.31
- SIGA $95.31
- P/E Ratio
- KMDA $27.53
- SIGA $9.91
- Revenue Growth
- KMDA 11.83
- SIGA N/A
- 52 Week Low
- KMDA $4.93
- SIGA $4.95
- 52 Week High
- KMDA $9.16
- SIGA $12.83
- Technical
- Relative Strength Index (RSI)
- KMDA 66.78
- SIGA 62.15
- Support Level
- KMDA $7.68
- SIGA $6.34
- Resistance Level
- KMDA $7.86
- SIGA $6.81
- Average True Range (ATR)
- KMDA 0.21
- SIGA 0.28
- MACD
- KMDA 0.05
- SIGA 0.02
- Stochastic Oscillator
- KMDA 67.61
- SIGA 83.75
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.